Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Santen Opens Office in Ho Chi Minh City
October 21, 2013
- Kissei, Kyorin Initiate PI Study of Overactive Bladder Treatment KEA-0447/KRP-EPA605
October 21, 2013
- Teva Pharma Japan to Discontinue Marketing 15% of All Products Under Selection and Concentration Strategy
October 18, 2013
- Amgen Making Fresh Start in the Japanese Market through Joint Venture with Astellas; Pathway to Independent Operation Remains Nebulous
October 18, 2013
- Eisai Inc to Increase Belviq Sales Reps to 400 in US
October 17, 2013
- Toho Pharmaceutical’s Logistics Base TBC Sapporo Starts Operations: Toho Holdings
October 17, 2013
- NBI, Eli Lilly Submit NDA for SGLT-2 Inhibitor
October 17, 2013
- Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President
October 16, 2013
- Otsuka Completes Acquisition of US Biotech Startup Astex
October 16, 2013
- Janssen, AZ to Copromote Prostate Cancer Treatment Abiraterone in Japan
October 16, 2013
- Once-Weekly DPP-4 Inhibitors of MSD, Takeda to Bring New Dimension to Packed Market
October 15, 2013
- Santen Launches Preservative-Free Tapros Mini Ophthalmic Solution
October 15, 2013
- Kowa Files for Approval of Glaucoma Treatment K-115
October 15, 2013
- Otsuka, Lundbeck Initiate Multinational PIII Program of Novel AD Treatment Lu AE58054
October 15, 2013
- Gilead to Enter Japan Full Force with Hepatitis C Treatment
October 11, 2013
- PAREXEL CEO Says Japan Will Remain as Important Market for CROs, Hopes Outsourcing Increases in Japan
October 11, 2013
- Ono to Set Up Local Subsidiary in South Korea, Eyeing Commercialization of Own Brands
October 11, 2013
- 36 Drug Makers Paid Approximately 400 Billion Yen to Doctors, Medical Institutions in FY2012; Mainly for R&D, But Also for Information
October 11, 2013
- 36 Drug Makers Spent 120 Billion Yen on Information Provision; Foreign-affiliated Companies Top Spending List
October 11, 2013
- DSP to Set Up New Anticancer Drug Sales Company in US, Eyes Launch of BBI608
October 10, 2013
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s drug pricing panel on November 19 discussed a wide range of potential pricing changes related to patent-protected medicines, including…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…